20/20 Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

20/20 Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$1.72M	Buy	10,482 +891	+9%	+$137K	0.44%	48
2021 Q1	$1.44M	Buy	9,591 +741	+8%	+$118K	0.42%	55
2020 Q4	$1.46M	Buy	8,850 +5,237	+145%	+$748K	0.43%	59
2020 Q3	$489K	Buy	+3,613	New	+$490K	0.18%	92

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

20/20 Capital Management's IBB Position: Q2 2021 in Review

20/20 Capital Management increased its iShares Biotechnology ETF (IBB) stake by 9.3% in Q2 2021, buying an estimated $137K and bringing the position to 10,482 shares worth $1.72M. The position accounts for 0.44% of the portfolio, ranked #48.

20/20 Capital Management first reported a position in IBB in Q3 2020 and has held it in 4 quarters since. 864 funds tracked by Wall St. Rank hold IBB as of Q2 2021.

20/20 Capital Management held 10,482 shares of iShares Biotechnology ETF worth $1.72M as of Q2 2021.
20/20 Capital Management bought 891 iShares Biotechnology ETF shares in Q2 2021, an estimated $137K.
iShares Biotechnology ETF made up 0.44% of 20/20 Capital Management's portfolio in Q2 2021, its #48 holding.
20/20 Capital Management first reported a position in iShares Biotechnology ETF in Q3 2020 and has held it in 4 quarters since.
864 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2021.

Based on 20/20 Capital Management's 13F filing for Q2 2021, filed 12 Jul 2021.